Back to News
Market Impact: 0.45
Definium Reports Second Phase III Success in Anxiety Disorder Program
Source: zacks.com
Healthcare & BiotechCorporate Guidance & Outlook
DFTX reported a second successful Phase III trial in generalized anxiety disorder, with DT120 ODT delivering statistically significant improvements in anxiety symptoms. The result supports planned FDA discussions and a targeted 2027 regulatory filing, materially advancing the drug candidate toward potential commercialization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
DFTX0.82
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Nasdaq futures sink 2.3% as Amazon, Intel and Alphabet send AI jitters through stocks
- Samsung hosts OpenAI’s Altman for talks on AI chips and infrastructure
- Why is iShares Semiconductor ETF plunging today?
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- AI for Investment Thesis Validation: A Claim-Ledger Method
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)